Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $11.45, for a total transaction of $1,145,000.00. Following the sale, the chief operating officer now owns 1,462,223 shares of the company's stock, valued at approximately $16,742,453.35. This represents a 6.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Tuesday, June 3rd, Eric Venker sold 566,278 shares of Roivant Sciences stock. The shares were sold at an average price of $11.22, for a total transaction of $6,353,639.16.
• On Monday, June 2nd, Eric Venker sold 433,722 shares of Roivant Sciences stock. The stock was sold at an average price of $11.07, for a total value of $4,801,302.54.
• On Tuesday, May 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.95, for a total transaction of $1,095,000.00.
• On Monday, April 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $10.22, for a total transaction of $1,022,000.00.

Roivant Sciences Stock Up 0.3%

Shares of NASDAQ:ROIV traded up $0.04 during midday trading on Tuesday, reaching $11.54. 7,283,806 shares of the company were exchanged, compared to its average volume of 5,614,795. The firm has a market cap of $7.85 billion, a PE ratio of -46.16 and a beta of 1.16. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $13.06. The stock has a fifty day simple moving average of $11.03 and a two-hundred day simple moving average of $10.93.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings results on Thursday, May 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.15). The business had revenue of $7.57 million for the quarter, compared to the consensus estimate of $62.17 million. Roivant Sciences had a negative return on equity of 14.76% and a negative net margin of 225.71%. During the same period in the prior year, the business earned ($0.23) earnings per share. As a group, analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ROIV. Parallel Advisors LLC lifted its stake in Roivant Sciences by 80.5% in the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company's stock valued at $25,000 after acquiring an additional 1,108 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Roivant Sciences by 478.6% during the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after purchasing an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in Roivant Sciences during the fourth quarter worth approximately $39,000. UMB Bank n.a. raised its stake in Roivant Sciences by 112.7% in the first quarter. UMB Bank n.a. now owns 4,143 shares of the company's stock valued at $42,000 after buying an additional 2,195 shares during the period. Finally, Fifth Third Bancorp lifted its position in shares of Roivant Sciences by 59.3% in the first quarter. Fifth Third Bancorp now owns 5,118 shares of the company's stock valued at $52,000 after buying an additional 1,905 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently commented on ROIV shares. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, June 18th.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.